Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.
Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, Krebsbach C, Patel RP, Karki C, Rosmarin D. Gorelick J, et al. Among authors: burge r. Dermatol Ther (Heidelb). 2019 Dec;9(4):785-797. doi: 10.1007/s13555-019-00334-1. Epub 2019 Oct 19. Dermatol Ther (Heidelb). 2019. PMID: 31630336 Free PMC article.
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Blauvelt A, et al. Among authors: burge r. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. J Eur Acad Dermatol Venereol. 2017. PMID: 28190255 Free PMC article. Clinical Trial.
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. Guenther L, et al. Among authors: burge r. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28573743 Clinical Trial.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group. Ryan C, et al. Among authors: burge r. Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22. Br J Dermatol. 2018. PMID: 29747232 Clinical Trial.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
Armstrong AW, Foster SA, Comer BS, Lin CY, Malatestinic W, Burge R, Goldblum O. Armstrong AW, et al. Among authors: burge r. BMC Dermatol. 2018 Jun 28;18(1):4. doi: 10.1186/s12895-018-0072-2. BMC Dermatol. 2018. PMID: 29954363 Free PMC article.
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A. Blauvelt A, et al. Among authors: burge r. J Dermatolog Treat. 2020 Mar;31(2):141-146. doi: 10.1080/09546634.2019.1587146. Epub 2019 Mar 18. J Dermatolog Treat. 2020. PMID: 30799638 Clinical Trial.
229 results